Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

antibody-drug conjugate ABBV-176

An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against the prolactin receptor (PRLR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ABBV-176 targets and binds to PRLR expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the PRLR-expressing tumor cells, through an as of yet unknown mechanism of action. PRLR, a tumor-associated antigen (TAA), is overexpressed by a variety of tumor cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	ADC ABBV-176
Code name:	ABBV 176 ABBV-176 ABBV176

antibody-drug conjugate ABBV-176

Search NCI's Drug Dictionary